What is it about?

When to treat smoldering multiple myeloma is controversial. Some randomized controlled trials (RCTs) have been conducted, but they used different treatment and had different results. This paper conducts a meta-analysis of these RCTs, and examines the optimal timing and therapy to treat smoldering multiple myeloma, especially high-risk patients.

Featured Image

Why is it important?

Smoldering multiple myeloma can progress to symptomatic multiple myeloma and can be lethal. But when to treat smoldering multiple myeloma has been controversial. Finding out when and how to manage smoldering multiple myeloma is important.

Perspectives

I hope this article can help doctors and researchers re-evaluate the timing to treat smoldering multiple myeloma. For high-risk patients, maybe early treatment could be benefit patients more.

Ailin Zhao
Peking Union Medical College Hospital

Read the Original

This page is a summary of: Early or deferred treatment of smoldering multiple myeloma: a meta-analysis on randomized controlled studies, Cancer Management and Research, June 2019, Dove Medical Press, DOI: 10.2147/cmar.s205623.
You can read the full text:

Read
Open access logo

Contributors

The following have contributed to this page